image credit: Unsplash

Moderna COVID-19 Vaccine 94.5% Effective in Early Phase III Data

Moderna said today that its COVID-19 vaccine candidate mRNA-1273 passed its most important test, the 30,000+ patient Phase III COVE trial (NCT04470427), by showing itself to be 94.5% effective in preventing COVID-19—an outcome hailed by CEO Stéphane Bancel as a “game changer.”

As a result, Moderna said, it will seek an emergency use authorization (EUA) from the FDA “in the coming weeks.” That EUA, Moderna said, is expected to be supported by final safety and efficacy data from the trial, with a median duration of at least two months.

Read More on Genetic Engineering and Biotechnology News